Image
Webcast Series

Setting a Course for the Optimal Management of IBD

An Interactive Learning Experience

ACG Clinical Guidelines: Management of Crohn's Disease in Adults.

Lichtenstein GR, et al. Am J Gastroenterol. 2018;113(4):481-517.

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.

Torres J, et al. J Crohns Colitis. 2020;14(1):4-22.

ACG Clinical Guideline: Ulcerative Colitis in Adults.

Rubin DT, et al. Am J Gastroenterol. 2019;114(3):384-413.

AGA Clinical Practice Guideline on the Management of Moderate to Severe Ulcerative Colitis.

Feuerstein JD, et al. Gastroenterology. 2020;158(5):1450-1461.

ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.

Farraye F, et al. Am J Gastroenterol. 2017;112(2):241-258.

Suggested Readings

Mechanism-based treatment strategies for IBD: cytokines, cell adhesion molecules, JAK inhibitors, gut flora, and more.

Schreiner P, et al. Inflamm Intest Dis. 2019;4(3):79-96.

From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting.

Mumolo MG, et al. World J Gastroenterol. 2018;24(33):3681-3694.

The role of laboratory tests in Crohn’s disease.

Cappello M, Morreale GC. Clin Med Insights Gastroenterol. 2016;9:51-62.

A treat-to-target update in ulcerative colitis: a systematic review.

Ungaro R, et al. Am J Gastroenterol. 2019;114(6):874-883.

Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.

Coskun M, et al. Pharmacol Res. 2013;76:1-8.

JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?

Danese S, et al. Gut. 2019;68(10):1893-1899.

Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis.

Olivera PA, et al. Gastroenterology. 2020;158(6):1554-1573.

Tofacitinib as induction and maintenance therapy for ulcerative colitis.

Sandborn WJ, et al. N Engl J Med. 2017;377(5):496-497.

SELECTION: filgotinib for ulcerative colitis.

Brierley R. Lancet Gastroenterol Hepatol. 2020;5(12):1036-1037.

Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.

Vermeire S, et al. Lancet. 2017;389(10066):266-275.

Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease.

Sandborn WJ, et al. Gastroenterology. 2020;158(8):2123-2138.

Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis.

Sandborn WJ, et al. Gastroenterology. 2020;158(8):2139-2149.

Patient Resources

American College of Gastroenterology

American Gastroenterological Association

Crohn’s and Colitis Foundation

European Crohn’s and Colitis Organisation

National Institute of Diabetes and Digestive and Kidney Diseases

Health Information for Crohn’s Disease

Health Information for Ulcerative Colitis

Relevant Resources

Targeting NASH

Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis

Hepatitis C is Curable

Got it? Treat it!

BLOCK HIV/HCV

Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

The Nexus of NASH and Type 2 Diabetes Mellitus

The Emerging Role of the Diabetologist

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

The Changing Landscape of IBD

Emerging Concepts in Patient Management

The Big (& Small) Picture of Nonalcoholic Steatohepatitis

Building Your Understanding to Combat a Growing Problem

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today

The Pursuit of Hepatitis C Elimination

How the Pharmacist Can Make a Difference

Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCV

Understanding the Growing Syndemic — Opioids, HCV, and HIV

Trends and Updates in IBD

Appraising the Therapeutic Armamentarium in Moderate and Severe Disease

Stepping Up to the Challenge

The PCP’s Role in HCV Elimination

BRIDGE HCV

Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV